Managed Healthcare Executive3d
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
This New Drug Could Help End the HIV Epidemic—but US Funding Cuts Are Killing Its Rollout
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
Queerty on MSN4d
A once-a-year PrEP injection? The results of the first clinical trial look promising
Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
BlackDoctor.org3d
Preparing for PrEP Side Effects
Like most prescribed medications, all three brands PrEP brands feature side effects. Here's how to prepare for them.
LGBTQ Nation on MSN3d
Once-a-year shot for HIV protection passes early safety trial
An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
MIT Technology Review3d
This annual shot might protect against HIV infections
In one, over 5,000 women and adolescent girls in Uganda and South Africa received either twice-yearly injections of lenacapavir or a daily PrEP pill. That trial was a resounding success ...
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.